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Abstract: The tumor necrosis factor–related weak inducer of apoptosis (TWEAK) belongs to the
tumor necrosis factor ligand superfamily, which was shown to play an important role in inflammatory
and malignant gastrointestinal diseases, including colitis or colorectal cancer. However, in contrast
to other members of the TNF ligand superfamily, its role as a biomarker in pancreatic cancer is
currently unknown. We analyzed serum levels of A proliferation-inducing ligand (APRIL) and
TWEAK in 134 patients with pancreatic cancer. Results were compared with 50 healthy controls and
correlated with clinical data. Intratumoral expression of APRIL and TWEAK in pancreatic cancer was
analysed using the datasets made available by the TCGA-LIHC project. APRIL serum levels were
significantly elevated in patients with pancreatic cancer compared to healthy controls, which is in
line with previous findings. Notably, the diagnostic accuracy of circulating APRIL levels was similar
to CA19-9, an established tumor marker for pancreatic cancer. In contrast, serum concentrations
of TWEAK were decreased in pancreatic cancer patients. Interestingly, no differences in TWEAK
concentrations became apparent between different clinical subgroups of pancreatic cancer. Moreover,
within our cohort of patients, TWEAK levels did not correlate with the patients’ prognosis and the
diagnostic as well as prognostic potential of TWEAK was lower than CA 19-9, when analyzed in this
setting. Finally, using data from the TCGA-LIHC project, we demonstrate that expression levels of
TWEAK and APRIL represent prognostic markers for patients’ survival according to Kaplan-Meier
curve analyses. TWEAK and APRIL serum concentrations are regulated differently in patients with
pancreatic cancer, highlighting diverse roles of variant TNF ligands in this type of cancer.
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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the 12th most common cancer worldwide [1].
Due to its unfavourable prognosis and the lack of effective treatment options at later stage of disease,
early diagnosis is essential to optimize possible treatment options and to improve patients’ outcome [2].
Therefore, new non-invasive diagnostic biomarkers could be a valuable addition to the existing
diagnostic work-up algorithms. Moreover, prognostic biomarkers could represent a useful tool
to divide pancreatic cancer patients into different subgroups, providing each patient an optimal
personalized therapeutic approach according to the individual likelihood to benefit from a specific
surgical, chemotherapeutic, or conservative treatment [3]. Currently, carbohydrate antigen (CA) 19-9
is the only biomarker for PDAC that is approved by the US Food and Drug Administration (FDA),
but its diagnostic sensitivity and specificity is poor [4–6].
Various reports have suggested a function of tumour necrosis factor (TNF) in the tumorigenesis
of PDAC [7,8]. The TNF superfamily ligands represent a class of type II transmembrane proteins,
exerting their biological activity as non-covalently bound trimers [9]. Activation of TNF receptor
(TNFR) members has been shown to play a pivotal role during infectious and inflammatory diseases.
Besides TNF, different members of the TNF ligand superfamily including A proliferation inducing
ligand (APRIL) and tumor necrosis factor–related weak inducer of apoptosis (TWEAK) have been
implicated in the pathogenesis of cancer [10–13].
In this context, different authors suggested that TWEAK promotes of apoptosis, cell growth as
well as angiogenesis. Blocking TWEAK in pancreatic cancer cell lines resulted in a 22–65% cell growth
inhibition of these cells, highlighting the therapeutic potential of this specific TNFR ligand in pancreatic
cancer [14]. In line, out of six patients, treated with Enavatuzumab, a humanized IgG1 antibody to the
TWEAK receptor, four demonstrated an objective tumor response. Moreover, some of these ligands
have been suggested to play a role as biomarkers in malignant disease. As such, elevated serum levels
of APRIL have been described in patients with pancreatic cancer [15–17] and were suggested to be a
diagnostic marker. Moreover APRIL levels were proposed to serve as a potential prognostic biomarker
to assess the outcome of these patients [18]. Despite the fact that alterations of TWEAK levels were
found in patients with different cancer as well as in patients with inflammatory or cardiovascular
diseases [19–21], the role of TWEAK serum concentrations in patients with PDAC remains unknown.
To analyse serum concentrations of TWEAK in patients with PDAC and to evaluate a potential
diagnostic or prognostic impact of TWEAK serum levels in these patients, we measured its serum
concentrations in 134 patients with pancreatic cancer at different stages of disease. Moreover,
TWEAK serum concentrations were correlated to patients’ characteristics such as tumour stage,
survival and routinely accessed laboratory parameters.
2. Patients and Methods
2.1. Study Design and Patient Characteristics
This observational cohort study was designed to evaluate TWEAK as a diagnostic or prognostic
serum marker in patients with pancreatic cancer. Patients were enrolled from University Hospital
RWTH Aachen and were prospectively recruited. 134 patients with pancreatic cancer (APRIL cohort
(n = 31): 58.1% male, 41.9% female, median age: 59 years, range 26–83 years; TWEAK cohort (n = 134):
56.7% male, 43.3% female, median age: 67.5 years, range 26–84 years; see Tables 1 and 2) were
diagnosed based on patients’ history, physical examination (silent jaundice, weight loss), imaging
techniques (CT, MRI) as well as laboratory tests (elevated AST, ALT, AP, GGT, bilirubin, and CA 19-9
concentration) and were further confirmed histopathologically after tumor resection. As a control
population, we analyzed 50 healthy, cancer-free blood donors with normal values for blood count,
C-reactive protein, and liver enzymes. The study protocol was approved by the local ethics committee
and conducted in accordance with the ethical standards laid down in the Declaration of Helsinki (ethics
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committee of the University Hospital Aachen, RWTH University, Aachen, Germany). Written informed
consent was obtained from the patients.
Table 1. Study population in the A proliferation inducing ligand (APRIL) cohort.
Parameter
Number 31
Sex (male/female) 18/13 (58.1/41.9%)
Age median (range) (years) 59 (26–83)
Staging
T1–T2–T3–T4 0–0–14–3 (0–0–45.2–9.7%)
N0–N1 5–11 (16.1–35.5%)
M0–M1 16–12 (51.6–38.7%)
G2–G3 11–7 (35.5–22.6%)
R0–R1–R2 9–3–1 (29.0–9.7–3.2%)
UICC
I–II–III–IV 0–17–1–12 (0–54.8–3.2–38.7%)
ECOG
ECOG 0 11 (35.5%)
ECOG I 17 (54.8%)
ECOG II 3 (9.7%)
ECOG III 0 (0%)
ECOG IV 0 (0%)
Fatigue
None 10 (32.2%)
Low 1 (3.2%)
Medium 9 (29.0%)
High 11 (35.5%)
Pain scale
0 13 (41.9%)
1–4 7 (22.6%)
5–7 9 (29.0%)
8–10 2 (6.5%)
CRP median (range) (mg/L) 8.0 (0.00–134.00)
Bilirubin median (range) (mg/L) 0.60 (0.20–26.20)
GGT median (range) (U/L) 218 (21–2138)
AP median (range) (U/L) 167 (64–1574)
AST median (range) (U/L) 28 (17–202)
ALT median (range) (U/L) 35 (15–451)
CEA median (range) (µg/L) 3.5 (1.2–16.0)
CA 19-9 median (range) (kU/L) 46 (2–10,000)
Creatinine median (range) (mg/dL) 0.8 (0.5–3.3)
WBC median (range) (cells/µg) 7.4 (5.4–10.5)
2.2. Determination of Serum APRIL and TWEAK Levels
Circulating levels of APRIL were determined using a commercial enzyme-linked immunosorbent
assay (ELISA) according to the manufacturers’ instructions (Product No. SEB750Hu, USCN Life
Science, Wuhan, China). The APRIL-ELISA represents a sandwich enzyme immunoassay for
the quantitative measurement of APRIL in human serum, plasma, and other biological fluids.
TWEAK serum concentrations were likewise analyzed using a commercially available ELISA
following the manufacturers’ instructions (Product No. O43508, Ray Biotech, Norcross, GA, USA).
The TWEAK-ELISA is a standard sandwich enzyme immunoassay for the quantitative measurement
of TWEAK in human serum, plasma, and cell culture supernatants.
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Table 2. Study population in the tumor necrosis factor–related weak inducer of apoptosis
(TWEAK) cohort.
Parameter
Number 134
Sex (male/female) 76/58 (56.7/43.3%)
Age median (range) (years) 67.50 (26–84)
Tumor type
IPMN 8 (6%)
PanIN 10 (7.5%)
PDAC 116 (86.6%)
Staging
T1–T2–T3–T4 2–3–66–8 (1.5–2.2–49.3–6%)
N0–N1 23–52 (17.2–38.9%)
M0–M1 88–36 (65.7–26.9%)
G2–G3 43–33 (32.1–24.6%)
R0–R1–R2 42–19–3 (31.3–14.2–2.2%)
UICC
I–II–III–IV 4–64–4–36 (3–47.8–3–26.9%)
ECOG
ECOG 0 60 (44.8%)
ECOG I 44 (32.8%)
ECOG II 39 (29.1%)
ECOG III 6 (4.5%)
ECOG IV 1 (0.7%)
Fatigue
None 45 (33.6%)
Low 19 (14.1%)
Medium 17 (12.7%)
High 21 (15.7%)
Pain scale
0 64 (47.8%)
1–4 12 (9%)
5–7 20 (14.9%)
8–10 6 (4.5%)
CRP median (range) (mg/L) 7.75 (0–237)
Bilirubin median (range) (mg/dL) 0.57 (0.15–26.20)
GGT median (range) (U/L) 107 (10–2138)
AP median (range) (U/L) 125.5 (39–1574)
AST median (range) (U/L) 27 (13–418)
ALT median (range) (U/L) 35 (7–569)
CEA median (range) (µg/L) 3 (0.22–76.30)
CA 19-9 median (range) (kU/L) 86.15 (0.6–266,567)
Creatinine median (range) (mg/dL) 0.82 (0.4–53.0)
WBC median (range) (cells/µL) 7.4 (2.7–23.30)
CRP, C-reactive protein; WBC, white blood cell count; AST, aspartate transaminase; ALT alanine transaminase;
GGT, γ-glutamyl-transpeptidase; AP, alkaline phosphatase; CEA, carcinoembryonic antigen; CA 19-9
carbohydrate antigen.
2.3. Statistical Analysis
Statistical analyses have been performed as recently described in detail [22–24]. In summary,
data are given as median and range to reflect the skewed distribution of analysis on human samples.
The Mann-Whitney-U-test and, for multiple comparisons, the Kruskal-Wallis-H-Test were used.
Box plot graphics display a statistical summary of the median, quartiles, and ranges. Correlations
analyses were performed using the Spearman correlation tests. Kaplan-Meier curves were plotted
to display the impact on the overall survival (OS). The optimal cut-off value for the identification
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of patients with an impaired OS was established using a recently published biometric software,
which fits Cox proportional hazard models to the dichotomized survival status (dead vs. alive) and
the survival variable (survival time). The optimal cut-off is hereby defined as the point with the most
significant (log-rank test) split [25]. The prognostic relevance of serum TWEAK was further tested
using univariate Cox-regression analysis. ROC curves were generated by plotting sensitivity against
1-specificity. All statistical analyses were performed with SPSS (SPSS 23, Chicago, IL, USA).
2.4. TGCA-PAAD
The raw data (count data) for messenger RNA data set were downloaded from (https://portal.
gdc.cancer.gov/projects/TCGA-PAAD). The miRNA datasets consisted of 178 samples that were
annotated regarding “tumor stage” (21 stage I, 146 stage II, 3 stage III, 5 stage IV; for 3 samples,
tumor stage was not reported. Differentially expressed genes were identified by using linear models
and moderated F- and t-statistics. Clinical data including the survival time of the patients were also
retrieved from TCGA data portal cBioPortal (http://www.cbioportal.org/index.do). Survival cut off
value was analyzed using the tool Cutoff Finder (http://molpath.charite.de/cutoff/) and used the
cut-off value to separate the patients’ survival on “low” and “high” expression. The percent survival
was calculated by GraphPad Prism Software.
3. Results
3.1. APRIL Serum Concentrations Are Elevated in Patients with Pancreatic Cancer
Elevated serum levels of APRIL were recently described in patients with PDAC [15–17].
To validate the suitability of our cohort of patients with pancreatic cancer as well as our general
analysis set-up to determine differences in serum concentrations of TNF ligands, we first measured
APRIL serum concentrations in a subgroup of patients and healthy controls (patients’ characteristics
are given in Table 1). Notably, this analysis revealed significantly higher levels of APRIL in PDAC
patients compared to healthy controls (Figure 1A). Based on this strong regulation, we next attempted
to compare the diagnostic accuracy of APRIL and CA19-9 for pancreatic cancer. In this analysis,
APRIL displayed an AUC value of 0.958 compared to 0.865 for CA19-9 (Figure 1B). Thus, these analyses,
which are in line with existing data, prove the suitability of our system to detect a potential regulation
in serum concentrations of members of the TNF ligand superfamily in patients with pancreatic cancer.
3.2. TWEAK Serum Concentrations Are Decreased in Patients with Pancreatic Cancer but Independent of the
Disease Stage
Next, we aimed to identify a potential role of TWEAK serum levels as a novel biomarker for
pancreatic cancer. We therefore analyzed serum levels of TWEAK in our cohort of 134 PDAC
patients and compared them to healthy controls (patients’ characteristics are given in Table 2).
Unexpectedly, this analysis revealed significantly lower serum levels of TWEAK in PDAC patients
compared to healthy controls (Figure 2A). Subsequently, we compared TWEAK serum concentrations
between different disease stages (T stages, nodal negative vs. positive disease, non-metastasized vs.
metastasized disease, moderately vs. poorly differentiated tumors). However, this analysis revealed
no significant differences between these subgroups of patients (Figure 2B–F). Moreover, serum levels
of TWEAK were unaltered in patients with incomplete tumor resection (R1) compared to patients with
complete tumor resection (R0) (Figure 2E) and did not correlate with clinical symptoms of pancreatic
cancer such as fatigue, pain or impaired ECOG performance status (Supplementary Figure S1).
To unravel potential mechanisms involved in the regulation of serum TWEAK concentrations, we next
analyzed potential correlations between TWEAK serum levels and routinely used laboratory markers.
In this analysis, TWEAK serum concentrations negatively correlated with serum levels of C-reactive
protein (r = −0.242, p = 0.010), which is contradictory to the assumption that tumors develop an
inflammatory microenvironment. It must be noted however that in our cohort the TWEAK serum
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levels were lower in patients suffering from PDAC than in healthy controls. Moreover, TWEAK levels
correlated negatively with serum levels of bilirubin (r = −0.179, p = 0.04), GGT (r = −0.212, p = 0.022),
and AP (r =−0.298, p = 0.001), which are commonly understood as markers for cholestasis in pancreatic
cancer (Table 3). Finally, we compared the diagnostic accuracy of TWEAK and CA19-9 for pancreatic
cancer. In this analysis, TWEAK displayed an AUC value of only 0.602 compared to 0.892 for CA19-9
(Figure 2G). In summary, these results suggest that, in contrast to APRIL, TWEAK serum levels are not
relevantly regulated in patients with PDAC and are therefore unsuitable as a diagnostic marker for
this setting.J. Clin. Med. 2018, 7, x FOR PEER REVIEW  6 of 13 
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Figure 1. APRIL serum concentrations are elevated in patients with pancreatic cancer. (A) Serum
concentrations of TWEAK were analyzed by enzyme-linked immunosorbent assay (ELISA) in patients
with pancreatic cancer and healthy blood donors as controls; (B) ROC curve analysis comparing the
diagnostic value of APRIL and CA19-9 for pancreatic cancer.
Table 3. Correlations of TWEAK and variant laboratory markers.
Parameter r p
AST −0.084 0.336
ALT −0.188 0.89
WBC 0.062 0.477
Bilirubin −0.179 0.04
GGT −0.212 0.022
AP −0.298 0.001
Albumin 0.338 0.008
CRP −0.242 0.010
Creatinine 0.085 0.333
CEA −0.050 0.664
CA 19-9 −0.072 0.507
r, correlation coefficient; p, p-value; r and p-values by Spearman rank correlation.
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Figure 2. TWEAK serum concentrations are decreased in patients with pancreatic cancer but are
independent of the disease stage. (A) Serum TWEAK concentrations were measured in patients with
pancreatic cancer and healthy blood donors as controls; (B–F) TWEAK levels were unaltered in patients
with different T-status, nodal positive vs. negative disease, metastasized vs. non-metastasized disease,
R0 and R1 resected patients, and different tumor gradings; (E) TWEAK levels were unaltered in patients
with R0 vs. R1 resection; (G) ROC curve analysis comparing the diagnostic value of TWEAK and
CA19-9 for pancreatic cancer.
3.3. TWEAK Serum Concentrations Do Not Predict Overall Survival in Patients with Pancreatic Cancer
Several studies have recently demonstrated a role of TNF ligand su rfamily members as
prognostic bio arkers in arious benign and malignant diseases. As an example, it wa shown
that elevated serum APRIL levels are indicative for tumor recurrence and an i paired prognosis after
resec i n of PDAC. To i entify a potential associ tion betwee TWEAK serum levels nd patients’
outcome, we compare TWEAK serum c ncentrations in patients that succumbed to death during the
follow-up period and survivors. Notably, this analysis revealed similar TWEAK serum levels between
these subgroups (Figure 3A), which was confirmed by an AUC of 0.564 for TWEAK when used to
distinguish between survivors and non-survivors (Figure 3B). To analyze the prognostic accuracy of
TWEAK serum concentrations, we next compared the overall survival of patients with high or low
initial TWEAK levels (above or below the 50th percentile). However, Kaplan-Meier curve analysis
revealed no significant difference between these groups (Figure 3C). We next established an ideal
prognostic TWEAK cut-off value by fitting Cox proportional hazard models to the survival status
and the survival time and tested for the most significant log-rank test as recently described [25].
This analysis revealed that a TWEAK serum level of 808.3 ng/mL best distinguishes between patients
with a good or poor postoperative prognosis. However, despite a strong trend towards an impaired
prognosis in patients with low TWEAK serum levels (below 808.3 ng/mL), this ideal cut-off value was
still unable to significantly identify a subgroup of patients with an impaired overall survival (Figure 3D).
In line, univariate Cox-regression analysis revealed that initial TWEAK serum concentrations were
unable to predict patients’ outcome after tumor resection (Hazard ratio: 1.000, p = 0.807), suggesting
that TWEAK serum levels do not reflect the postoperative prognosis of PDAC patients undergoing
surgical tumor resection.
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Figure 3. TWEAK serum concentrations do not predict survival in patients with pancreatic cancer.
(A) Serum TWEAK concentrations were measured in patients that succumbed to death and survivors;
(B) ROC curve analyses determining the prognostic value of TWEAK in patients with pancreatic
cancer; (C) Kaplan-Meier curve analysis with respect to patients’ serum TWEAK concentrations (cut-off
determined by using the median); (D) Kaplan-Meier curve analysis with respect to patients’ serum
TWEAK concentrations (ideal cut-off value).
3.4. Tissue APRIL and TWEAK Expression as a Predictor for Patients Survival
Based on these results we next attempted at examining a molecular function of APRIL and
TWEAK in pancreatic cancer as well as the role of intratumoral TWEAK and APRIL expression as a
predictor for patients survival. Considering the lack of corresponding tissue samples for the analyzed
serum samples, we analyzed the expression of APRIL and TWEAK within the datasets made available
by the TCGA-LIHC project. We therefore downloaded the raw data (count data) the messenger
RNA data set. The datasets consisted of 178 samples that were annotated regarding “tumor stage”
(4 normal, 21 stage I, 146 stage II, 3 stage III, 5 stage IV; for 3 samples tumor stage was not reported).
These results showed that TWEAK but not APRIL was significantly lower expressed in tumor vs
non-tumor tissue (p = 0.020 and 0.60; respectively; Figure 4A,B), being fully consistent with the results
we presented regarding lower levels of TWEAK in serum of patients with pancreatic cancer (Figure 2A).
Strikingly low serum concentrations of TWEAK but not APRIL turned out as a significant prognostic
marker for patients’ survival according to Kaplan-Meier curve analysis (Figure 4C,D), highlighting
the relevance of TWEAK in the pathogenesis of pancreatic cancer. Finally, intratumoral TWEAK and
APRIL expression were strongly correlated, underlining that common mechanism might be involved
in the regulation of these TNFR ligands in pancreatic cancer.
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pancreatic cancer. The raw data (count data) for messenger RNA data set were downloaded from
(https://portal.gdc.cancer.gov/projects/TCGA-PAAD). (A) Relative TWEAK expression levels are
depicted; (B) Relative APRIL expression levels are depicted (C) Kaplan-Meier curve analysis with
respect to patients’ TWEAK expression; (D) Kaplan-Meier curve analysis with respect to patients’
TWEAK expression; (E) Correlation analysis between relative TWEAK and APRIL expression.
4. Discussion
TNF has been widely implicated in the pathophysiology of different cancers including pancreatic
carcinoma [7,8]. Increased levels of APRIL, a bona fide member of the TNF ligand superfamily,
were previously demonstrated in the serum of patients with pancreatic cancer and were shown to
correlate with early tumor recurrence and an impaired patients’ prognosis [15–17], suggesting that
other members of the TNF superfamily might hold a similar role. In this context, elevated tissue
expression levels of TWEAK were reported from patients with pancreatic cancer when compared to
patients with chronic pancreatitis or healthy controls. In this study, we analyzed TWEAK serum levels
in a large and well characterized cohort of patients with pancreatic cancer at different disease stages.
Unexpectedly, in our cohort of patients, TWEAK levels were independent of the disease stage and
did not reflect patients’ outcome, highlighting that different members of the TNF ligand superfamily
(such as APRIL or TWEAK) might have different roles in the pathophysiology of this disease and
might reflect different aspects of the pathophysiology of pancreatic cancer when used as a biomarker
in this setting.
PDAC represents one of the most devastating diagnoses to date. Only in case of early diagnosis
are curative treatment approaches available [2]. Thus, diagnostic modalities allowing tumour detection
at an early time-point might have an important role in the treatment of PDAC. However, at present,
besides measurement of CA19-9, no serum-based (and therefore easily accessible) biomarker has a
sufficient sensitivity or specificity to be used in clinical routine [26]. Recent research in the context of
PDAC and other cancers suggest that innovative molecules such as TNF receptor ligands might
overcome these limitations [26]. In this study, we demonstrate that the diagnostic accuracy of
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APRIL is superior to that of CA19-9 measurements in patients with PDAC. Besides being used in the
context of diagnosis, treatment predictive and prognostic biomarkers might have an essential role in
providing an optimal and personalized treatment to patients with pancreatic cancer. Despite a major
scientific effort during the last decades, the ideal biomarker for these purposes has not been identified
yet. The combination of different markers as diagnostic or prognostic indices appears promising.
One might therefore speculate that a combination of different TNF ligand superfamily members with
CA 19-9 might further improve the diagnostic and prognostic accuracy of these markers. Nevertheless,
larger studies, featuring a longitudinal and multicentre design are needed to validate these novel
biomarkers and to further evaluate the clinical potential of such marker combinations.
Based on their deep integration into the pathophysiology of many diseases, the use of TNF
ligand superfamily members as biomarkers represents a biologically plausible concept. To prove the
suitability of our cohort of patients for detecting differences in TNF ligand superfamily members in
PDAC-patients and healthy controls, we first analyzed concentrations of APRIL, which is known to
be deregulated in pancreatic cancer in a smaller subgroup of our cohort. Importantly, these analyses
were in line to all previous reports, enabling us to analyze serum levels of TWEAK in all patients
included in this study. Conversely to APRIL, TWEAK levels were significantly lower in patients with
pancreatic cancer when compared with healthy controls. Moreover, while levels of APRIL have been
demonstrated to reflect disease characteristics, no similar correlation was detected for TWEAK in this
context. These striking differences between different members of the TNF ligand superfamily are
confirmed by similar differences between these and other members of the superfamily in patients
with critical illness and sepsis. As such, we recently demonstrated that both TNF and APRIL serum
levels are up-regulated in patients with sepsis, while serum levels of TWEAK were down-regulated
and serum levels of GITRL were unchanged [21,27]. Thus, it seems likely that the observation on
a distinct regulation of APRIL and TWEAK is not a “random phenomenon” but rather reflects a
different role of these molecules in the pathophysiology of pancreatic cancer. In this context, the
role of TWEAK in the pathophysiology of pancreatic cancer is of especial interest, as it has been
demonstrated that pronounced therapeutic effects are achievable with soluble TWEAK-antibodies in a
variety of disease models [28]. Consequently, TWEAK-specific antibodies are currently being tested
in the context of inflammatory diseases and in patients with solid tumors [28]. Besides anti-TWEAK
antibodies, Tigatuzumab, a humanized version of the agonistic murine monoclonal antibody TRA-8,
directed against TRAIL, another member of the TNF ligand superfamily, is under investigation in
patients with pancreatic cancer [29], highlighting the therapeutic potential of these ligands.
Similar to sepsis, PDAC results in local and systemic inflammation [30]. Thus, our data on a
different regulation of different members of the TNF ligand superfamily might reflect different roles of
these proteins in the complex regulation of the inflammatory response during the disease progress of
patients suffering from PDAC. In this context, it is important to note that PDAC results in a strong
activation of the NF-KB pathway, which is the common signaling pathway of all members of the TNF
ligand superfamily. NF-κB also functions as a key link between pancreatic inflammation and cancer [31].
It was demonstrated that macrophages from patients with chronic pancreatitis secrete increased
amounts of TNF [32]. Thus, the differential regulation of different TNF ligand superfamily members
might reflect an adaption mechanism of activated macrophages towards different inflammatory stimuli
during the development of PDAC.
In summary, our data clearly argue against a potential use of TWEAK serum levels as a biomarker
in patients with PDAC. Nevertheless, from a basic scientific view, our data suggest that different TNF
superfamily members might exert different roles in the development of PDAC. These data should
trigger further research using e.g., animal models to shed light on the specific roles of TWEAK and
other TNFR ligands in in PDAC.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/7/7/175/s1.
Figure S1: Serum levels of TWEAK in different subgroups of patients with pancreatic cancer.
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